Arrowhead (ARWR) announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 and apolipoprotein C3 genes.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $101 from $61 at B. Riley
- Arrowhead price target raised to $100 from $85 at H.C. Wainwright
- Arrowhead price target raised to $110 from $100 at Piper Sandler
- Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
- Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch